Empowering people, informing care decisions.
At Castle, it all comes down to people. After all, disease doesn’t just happen — it happens to people. We believe that disease management and treatment decisions can be better informed through a person’s unique biology, which is revealed through the scientific rigor of our innovative tests. We are committed to empowering healthcare providers and patients with the goal of improved outcomes.
Clinical focus areas
Our broad portfolio of innovative tests focuses on answering critical clinical questions. Our tests are designed to deliver personalized information that better informs care decisions.
.svg)
Featured spotlights
This article, part of the 2025 USA TODAY Skin Health Campaign, highlights how DecisionDx-Melanoma empowers patients and clinicians to co-create individualized care plans based on tumor biology. Featuring patient advocate Leah Bressler, it emphasizes how 31-GEP testing provides both clinical clarity and peace of mind.
[.underline-move-left]This study[.underline-move-left] is a prospective, multi-center study that assessed the effect of 31-GEP testing on SLNB performance rates in patients with T1–T2 tumors considering SLNB and studied long-term outcomes of patients with a Class 1A result (n=130). Of these low-risk patients, 63 had an SLNB, with a 3.2% SLN positivity rate (2/63). No Class 1A patients, regardless of SLN status, experienced a recurrence (2-year median follow-up). These results are consistent with previous studies showing that the 31-GEP can identify patients at low risk of SLN positivity and recurrence.
Despite definitive surgical treatment, a subset of cutaneous squamous cell carcinomas (cSCC) has an increased risk of regional or distant metastasis, making it challenging to identify patients most at risk. The 40-gene expression profile (40-GEP) prognostic test improves risk stratification for patients with cSCC who have known clinical or histologic risk factors, categorizing their risk of metastasis as low (Class 1), higher (Class 2A), or highest (Class 2B).
.webp)
Brent Moody, MD, FACP, FAAD discusses how MyPath Melanoma raised red flags in a 26-year-old patient with multiple pigmented lesions.
It's melanoma.
Now what?
Know your risk and navigate your melanoma journey with confidence
It's melanoma.
Now what?
Know your risk and navigate your melanoma journey with confidence
Relentless pursuit of the best outcomes
At Castle, we combine innovation, advanced technologies and relevant real-world evidence to address critical unmet clinical needs and improve health outcomes.
The validity and utility of Castle’s innovative tests has been demonstrated in more than 150 peer-reviewed publications, and more than 300,000 test reports have been delivered to clinicians since 2008 to guide improved disease management decisions for patients.
The latest
Press Release
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
Press Release
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug...
Press Release
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
We are transforming disease management. Join in the transformation.
Every employee at Castle has an impact on patient care. If you are interested in making a difference in the lives of patients while doing something that inspires you, find out what exciting opportunities are available within our team.
%402x.b1d6d28a.webp)